What is AlloVir Financial Strength?
AlloVir has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
GuruFocus does not calculate AlloVir's interest coverage with the available data.
As of today, AlloVir's Altman Z-Score is 0.00.
Competitive Comparison of AlloVir's Financial Strength
For the Biotechnology subindustry, AlloVir's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AlloVir's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AlloVir's Financial Strength distribution charts can be found below:
* The bar in red indicates where AlloVir's Financial Strength falls into.
AlloVir Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
AlloVir's Interest Expense for the
months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the
months ended in Dec. 2023 was $-43.84 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $16.65 Mil.
AlloVir's Interest Coverage for the quarter that ended in Dec. 2023 is
| GuruFocus does not calculate AlloVir's interest coverage with the available data. |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. AlloVir Inc has enough cash to cover all of its debt. Its financial situation is stable.
2. Debt to revenue ratio. The lower, the better.
AlloVir's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
AlloVir has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AlloVir (AlloVir) Business Description
Traded in Other Exchanges
N/A
Address
1100 Winter Street, Waltham, MA, USA, 02451
AlloVir Inc is a late clinical-stage cell therapy company. It is developing allogeneic T-cell therapies to treat and prevent devastating viral diseases. The firm's pipeline includes ALVR106, ALVR109, ALVR108, and others. The company's product candidate, Viralym-M, is a multi-VST therapy targeting five viruses namely BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6.
Executives
| Vikas Sinha |
director, 10 percent owner, officer: See Remarks |
C/O ALEXION PHARMACUETICALS, INC., 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
| Diana Brainard |
director |
C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
| Edward Miller |
officer: General Counsel |
C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
| Brett R Hagen |
officer: Chief Accounting Officer |
200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
| Gilead Sciences Inc |
10 percent owner |
333 LAKESIDE DR, FOSTER CITY CA 94404 |
| Cintia Piccina |
officer: Chief Commercial Officer |
60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 X0 OX14 4R |
| Derek N. Adams |
director |
ALLOVIR, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Van Beek Jeroen B |
officer: Chief Commercial Officer |
C/O TRICIDA, INC., 7000 SHORELINE COURT, SUITE 201, SOUTH SAN FRANCISCO CA 94080 |
| Ercem Atillasoy |
officer: See Remarks |
C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142 |
| David Hallal |
director, 10 percent owner, officer: Chief Executive Officer |
C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410 |
| F2 - Tpo Investments Llc |
director, 10 percent owner |
C/O SINGER, MCKEON INC., 8 W 38TH ST SUITE 1001, NEW YORK NY 10018 |
| F2 Bioscience Av 2022 Llc |
director, 10 percent owner |
8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018 |
| Capital I 2020 F2 |
director, 10 percent owner |
8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018 |
| F2 Mc, Llc |
director, 10 percent owner |
8 WEST 38TH STREET, SUITE 1001, NEW YORK NY 10018 |
| Globeways Holdings Ii Ltd |
director, 10 percent owner |
C/O SINGER, MCKEON INC., 8 W 38TH ST. STE. 1001, NEW YORK NY 10018 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ALVR has been successfully added to your